Vaxart (NASDAQ:VXRT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vaxart (NASDAQ:VXRT) to a buy rating in a research note released on Friday morning.

Vaxart Trading Up 1.5%

NASDAQ:VXRT opened at $0.67 on Friday. The firm has a market capitalization of $161.08 million, a PE ratio of -2.48 and a beta of 0.95. Vaxart has a 52 week low of $0.26 and a 52 week high of $0.84. The stock has a 50 day moving average of $0.43 and a 200-day moving average of $0.39.

Institutional Trading of Vaxart

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart during the first quarter worth $31,000. Creative Planning acquired a new stake in shares of Vaxart during the 2nd quarter valued at about $33,000. Invesco Ltd. increased its stake in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares during the last quarter. Raymond James Financial Inc. increased its position in Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after buying an additional 34,075 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 478,111 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.